Beagle BioTech closes Series A led by Tri Wise Capital

Beagle BioTech recently completed a series A round of financing worth tens of millions of yuan, which was invested by Tri Wise Capital. It is a new round of financing by Beagle BioTech after the 30-million-yuan angel round in 2018.

Beagle BioTech recently completed a series A round of financing worth tens of millions of yuan, which was invested by Tri Wise Capital. It is a new round of financing by Beagle BioTech after the 30-million-yuan angel round in 2018.

Beagle BioTech is a biotechnology innovation enterprise jointly established by a team of overseas returnees and a domestic local pharmaceutical company. The company is engaged in the research and clinical application of exosomes technology.

According to some reports, Beagle BioTech has completed the construction of an extraction and analysis platform, and has been approved to set up a third-party medical inspection platform.

Beagle BioTech aims to reduce the cost for testing through vitro diagnosis of blood exosomes, so that small and medium-sized hospitals and medical testing institutions can do the testing. As a result, a large number of middle-aged and elderly people who have Alzheimer’s disease can be diagnosed and treated.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/08/19/beagle-biotech-closes-series-a-led-by-tri-wise-capital/.

Leave a Reply

Please Login to Comment